Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.
暂无分享,去创建一个
[1] J. Lustgarten,et al. Flagellin Fusion Proteins as Adjuvants or Vaccines Induce Specific Immune Responses , 2004, Infection and Immunity.
[2] A. Krieg,et al. CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.
[3] M. Toda,et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.
[4] Hailing Lu,et al. IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice1 , 2006, The Journal of Immunology.
[5] E. Jaffee,et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response , 2005, The Journal of experimental medicine.
[6] E. Shevach,et al. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. , 1998, Journal of immunology.
[7] P. Ohashi,et al. Immunological function of a defined T-cell population tolerized to low-affinity self antigens , 1995, Nature.
[8] C. Pinilla,et al. Identification of Cross-Reactive Peptides Using Combinatorial Libraries Circumvents Tolerance against Her-2/neu-Immunodominant Epitope1 , 2006, The Journal of Immunology.
[9] Wei-Zen Wei,et al. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. , 2005, Cancer research.
[10] S. Batra,et al. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. , 2005, Cancer research.
[11] T. Elliott,et al. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens , 2002, European journal of immunology.
[12] J. Price,et al. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice , 2001, Cancer Gene Therapy.
[13] B. Rouse,et al. CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell Responses , 2003, The Journal of experimental medicine.
[14] Joshua M. Korn,et al. The plasticity of dendritic cell responses to pathogens and their components. , 2001, Science.
[15] C. Janeway. Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.
[16] S. Kaufmann,et al. Regulatory CD4+CD25+ T Cells Restrict Memory CD8+ T Cell Responses , 2002, The Journal of experimental medicine.
[17] J. Lustgarten,et al. Aged Mice Develop Protective Antitumor Immune Responses with Appropriate Costimulation1 , 2004, The Journal of Immunology.
[18] J. Shimizu,et al. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.
[19] S. Akira,et al. MyD88 as a bottle neck in Toll/IL-1 signaling. , 2002, Current topics in microbiology and immunology.
[20] W. Gillanders,et al. Defining the Antigen-Specific T-Cell Response to Vaccination and Poly(I:C)/TLR3 Signaling: Evidence of Enhanced Primary and Memory CD8 T-Cell Responses and Antitumor Immunity , 2005, Journal of immunotherapy.
[21] R. Medzhitov. Approaching the asymptote: 20 years later. , 2009, Immunity.
[22] P. Musiani,et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. , 2000, Cancer research.
[23] S. Akira,et al. Toll receptors and pathogen resistance , 2003, Cellular microbiology.
[24] J. Lustgarten,et al. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged , 2008, Cancer Immunology, Immunotherapy.
[25] J. Lustgarten,et al. Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. , 2003, Cancer research.
[26] T. Nomura,et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.
[27] T. Watts,et al. TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.
[28] P. Lollini,et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti‐OX40 and anti‐4‐1BB monoclonal antibodies induces T cell–mediated protective immunity in Her‐2/neu transgenic mice , 2005, International journal of cancer.
[29] B. Monks,et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome , 2004, Nature Immunology.
[30] A. Rudensky,et al. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.
[31] T. Schumacher,et al. Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?1 , 2002, The Journal of Immunology.
[32] M. Bevan,et al. Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.
[33] Ruslan Medzhitov,et al. Control of adaptive immune responses by Toll-like receptors. , 2002, Current opinion in immunology.
[34] G. Forni,et al. Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice1 , 2006, The Journal of Immunology.
[35] L. Turka,et al. Tregs and transplantation tolerance. , 2004, The Journal of clinical investigation.
[36] D. Kohn,et al. Immune response to green fluorescent protein: implications for gene therapy , 1999, Gene Therapy.
[37] P. Musiani,et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. , 2006, Cancer research.
[38] J. Lustgarten,et al. The CD8+ T cell repertoire against Her‐2/neu antigens in neu transgenic mice is of low avidity with antitumor activity , 2004, European journal of immunology.
[39] E. Celis,et al. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] E. Shevach,et al. The GITR–GITRL interaction: co-stimulation or contrasuppression of regulatory activity? , 2006, Nature Reviews Immunology.
[41] L. Liau,et al. The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity1 , 2006, The Journal of Immunology.
[42] J. Wolchok,et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. , 2006, Cancer research.
[43] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[44] M. Colombo,et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. , 2005, Blood.
[45] D. A. Foster,et al. Regulation of mTOR by phosphatidic acid? , 2007, Cancer Research.
[46] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.
[47] E. Shevach,et al. Control of T‐cell activation by CD4+ CD25+ suppressor T cells , 2001, Immunological reviews.
[48] A. Caton,et al. Activation of CD4+CD25+ regulatory T cell suppressor function by analogs of the selecting peptide , 2007, European journal of immunology.
[49] S. Sakaguchi,et al. Regulatory T Cells in Immunologic Self-Tolerance and Autoimmune Disease , 2005, International reviews of immunology.
[50] D. Kioussis,et al. Tracing and characterization of the low‐avidity self‐specific T cell repertoire , 2000, European journal of immunology.
[51] L. Pease,et al. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. , 2007, Cancer research.